

Worldwide Genocide Continues: 13,867 Dead and 1,354,336 Injuries in European Database of Adverse Drug Reactions for COVID-19 Shots

By [Brian Shilhavy](#)

Global Research, June 08, 2021

[Health Impact News](#) 7 June 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg_globalresearch](#).

The European database of suspected drug reaction reports is [EudraVigilance](#), which also tracks reports of injuries and deaths following the experimental COVID-19 “vaccines.”

Here is what [EudraVigilance](#) states about their database:

This website was launched by the [European Medicines Agency](#) in 2012 **to provide public access to reports of suspected side effects** (also known as suspected adverse drug reactions). These reports are submitted electronically to [EudraVigilance](#) by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.

EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA). EudraVigilance has been in use since December 2001.

This website was launched to comply with the [EudraVigilance Access Policy](#), which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.

The [Management Board of the European Medicines Agency](#) first approved the EudraVigilance Access Policy in December 2010. A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation. The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.

Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is

better able to address the growing need among stakeholders, including the general public, for access to information. ([Source.](#))

Their report through June 5, 2021 lists **13,867 deaths and 1,354,336 injuries** following injections of four experimental COVID-19 shots:

- [COVID-19 MRNA VACCINE MODERNA \(CX-024414\)](#)
- [COVID-19 MRNA VACCINE PFIZER-BIONTECH](#)
- [COVID-19 VACCINE ASTRAZENECA \(CHADOX1 NCOV-19\)](#)
- [COVID-19 VACCINE JANSSEN \(AD26.COV2.S\)](#)

From the total of injuries recorded, there are 683,688 **serious** injuries which equals over 50%.

*“**Seriousness** provides information on the suspected undesirable effect; it can be classified as ‘serious’ if it corresponds to a medical occurrence that results in **death**, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.”*

A *Health Impact News* subscriber in Europe ran the reports for each of the four COVID-19 shots we are including here. This subscriber has volunteered to do this, and it is a lot of work to tabulate each reaction with injuries and fatalities, since there is no place on the [EudraVigilance](#) system we have found that tabulates all the results.

Since we have started publishing this, others from Europe have also calculated the numbers and confirmed the totals.[1]

Here is the summary data through June 5, 2021.

Total reactions for the experimental mRNA vaccine **Tozinameran** (code **BNT162b2, Comirnaty**) from **BioNTech/ Pfizer: 6,732 deaths** and **502,162** injuries to 05/06/2021

- 14,819 Blood and lymphatic system disorders **incl. 74 deaths**
- 11,018 Cardiac disorders **incl. 843 deaths**
- 90 Congenital, familial and genetic disorders **incl. 5 deaths**
- 6,146 Ear and labyrinth disorders **incl. 3 deaths**
- 216 Endocrine disorders
- 7,119 Eye disorders **incl. 17 deaths**
- 45,616 Gastrointestinal disorders **incl. 332 deaths**
- 140,516 General disorders and administration site conditions **incl. 2,079 deaths**
- 387 Hepatobiliary disorders **incl. 28 deaths**
- 5,436 Immune system disorders **incl. 32 deaths**
- 15,632 Infections and infestations **incl. 711 deaths**
- 5,552 Injury, poisoning and procedural complications **incl. 94 deaths**
- 11,782 Investigations **incl. 260 deaths**
- 3,730 Metabolism and nutrition disorders **incl. 129 deaths**
- 71,816 Musculoskeletal and connective tissue disorders **incl. 84 deaths**
- 295 Neoplasms benign, malignant and unspecified (incl cysts and polyps)

incl. 21 deaths

- 90,427 Nervous system disorders **incl. 692 deaths**
- 330 Pregnancy, puerperium and perinatal conditions **incl. 11 deaths**
- 100 Product issues
- 8,902 Psychiatric disorders **incl. 99 deaths**
- 1,547 Renal and urinary disorders **incl. 103 deaths**
- 2,052 Reproductive system and breast disorders **incl. 3 deaths**
- 21,055 Respiratory, thoracic and mediastinal disorders **incl. 777 deaths**
- 23,678 Skin and subcutaneous tissue disorders **incl. 60 deaths**
- 750 Social circumstances **incl. 9 deaths**
- 222 Surgical and medical procedures **incl. 15 deaths**
- 12,929 Vascular disorders **incl. 251 deaths**

Total reactions for the experimental mRNA vaccine **mRNA-1273(CX-024414)** from **Moderna: 3,821 deaths** and **101,767 injuries** to 05/06/2021

- 1,826 Blood and lymphatic system disorders **incl. 27 deaths**
- 2,822 Cardiac disorders **incl. 409 deaths**
- 31 Congenital, familial and genetic disorders **incl. 2 deaths**
- 1,171 Ear and labyrinth disorders
- 64 Endocrine disorders **incl. 1 death**
- 1,575 Eye disorders **incl. 5 deaths**
- 8,770 Gastrointestinal disorders **incl. 124 deaths**
- 28,047 General disorders and administration site conditions **incl. 1,646 deaths**
- 180 Hepatobiliary disorders **incl. 10 deaths**
- 936 Immune system disorders **incl. 5 deaths**
- 3,333 Infections and infestations **incl. 219 deaths**
- 2,013 Injury, poisoning and procedural complications **incl. 71 deaths**
- 2,292 Investigations **incl. 85 deaths**
- 1,137 Metabolism and nutrition disorders **incl. 77 deaths**
- 12,483 Musculoskeletal and connective tissue disorders **incl. 69 deaths**
- 113 Neoplasms benign, malignant and unspecified (incl cysts and polyps) **incl. 14 deaths**
- 17,861 Nervous system disorders **incl. 382 deaths**
- 171 Pregnancy, puerperium and perinatal conditions **incl. 1 death**
- 18 Product issues
- 2,071 Psychiatric disorders **incl. 61 deaths**
- 670 Renal and urinary disorders **incl. 46 deaths**
- 352 Reproductive system and breast disorders **incl. 1 death**
- 4,831 Respiratory, thoracic and mediastinal disorders **incl. 365 deaths**
- 5,412 Skin and subcutaneous tissue disorders **incl. 25 deaths**
- 427 Social circumstances **incl. 12 deaths**
- 311 Surgical and medical procedures **incl. 33 deaths**
- 2,850 Vascular disorders **incl. 131 deaths**

Total reactions for the experimental vaccine **AZD1222/VAXZEVRIA (CHADOX1 NCOV-19)** from **Oxford/ AstraZeneca: 2,848 deaths** and **724,457 injuries** to 05/06/2021

- 8,125 Blood and lymphatic system disorders **incl. 117 deaths**
- 10,935 Cardiac disorders **incl. 351 deaths**
- 97 Congenital, familial and genetic disorders **incl. 2 deaths**
- 7,746 Ear and labyrinth disorders
- 263 Endocrine disorders **incl. 2 deaths**
- 11,998 Eye disorders **incl. 10 deaths**
- 75,897 Gastrointestinal disorders **incl. 129 deaths**
- 195,671 General disorders and administration site conditions **incl. 769 deaths**
- 450 Hepatobiliary disorders **incl. 24 deaths**
- 2,765 Immune system disorders **incl. 11 deaths**
- 15,657 Infections and infestations **incl. 188 deaths**
- 6,783 Injury, poisoning and procedural complications **incl. 57 deaths**
- 15,030 Investigations **incl. 62 deaths**
- 9,083 Metabolism and nutrition disorders **incl. 42 deaths**
- 113,983 Musculoskeletal and connective tissue disorders **incl. 30 deaths**
- 275 Neoplasms benign, malignant and unspecified (incl cysts and polyps) **incl. 8 deaths**
- 155,571 Nervous system disorders **incl. 438 deaths**
- 190 Pregnancy, puerperium and perinatal conditions **incl. 3 deaths**
- 88 Product issues
- 13,563 Psychiatric disorders **incl. 25 deaths**
- 2,518 Renal and urinary disorders **incl. 23 deaths**
- 4,578 Reproductive system and breast disorders
- 23,942 Respiratory, thoracic and mediastinal disorders **incl. 322 deaths**
- 33,090 Skin and subcutaneous tissue disorders **incl. 18 deaths**
- 678 Social circumstances **incl. 4 deaths**
- 571 Surgical and medical procedures **incl. 16 deaths**
- 14,910 Vascular disorders **incl. 197 deaths**

Total reactions for the experimental **COVID-19 vaccine JANSSEN (AD26.COV2.S) from Johnson & Johnson: 466 deaths** and **25,950 injuries** to 05/06/2021

- 240 Blood and lymphatic system disorders **incl. 13 deaths**
- 392 Cardiac disorders **incl. 48 deaths**
- 12 Congenital, familial and genetic disorders
- 125 Ear and labyrinth disorders
- 6 Endocrine disorders **incl. 1 death**
- 305 Eye disorders **incl. 3 deaths**
- 2,389 Gastrointestinal disorders **incl. 18 deaths**
- 6,643 General disorders and administration site conditions **incl. 120 deaths**
- 44 Hepatobiliary disorders **incl. 3 deaths**
- 66 Immune system disorders
- 322 Infections and infestations **incl. 11 deaths**
- 267 Injury, poisoning and procedural complications **incl. 7 deaths**
- 1,683 Investigations **incl. 32 deaths**
- 140 Metabolism and nutrition disorders **incl. 10 deaths**
- 4,429 Musculoskeletal and connective tissue disorders **incl. 14 deaths**
- 14 Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- 5,457 Nervous system disorders **incl. 57 deaths**

- 9 Pregnancy, puerperium and perinatal conditions **incl. 1 death**
- 8 Product issues
- 275 Psychiatric disorders **incl. 3 deaths**
- 102 Renal and urinary disorders **incl. 7 deaths**
- 85 Reproductive system and breast disorders
- 907 Respiratory, thoracic and mediastinal disorders **incl. 37 deaths**
- 556 Skin and subcutaneous tissue disorders **incl. 1 death**
- 62 Social circumstances **incl. 3 deaths**
- 293 Surgical and medical procedures **incl. 23 deaths**
- 1,119 Vascular disorders **incl. 54 deaths**

Last Update: Jun 05 2021	Reported Cases	Fatalities	% fatalities to cases	All Multiple Symptoms	Serious injuries	% serious to ALL
Astrazeneca	264 549	2 848	1,08%	724 457	404 748	55,87%
Pfizer-BioNTech	212 053	6 732	3,17%	502 162	210 964	42,01%
Moderna	40 712	3 821	9,39%	101 767	58 174	57,16%
Janssen	8 593	466	5,42%	25 950	9 802	37,77%
Total:	525 907	13 867	2,64%	1 354 336	683 688	50,48%

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Notes

[1] These totals are estimates based on reports submitted to [EudraVigilance](#). Totals may be much higher based on percentage of adverse reactions that are reported. Some of these reports may also be reported to the individual country's adverse reaction databases, such as the U.S. VAERS database, and the UK Yellow Card system. The fatalities are grouped by symptoms, and some fatalities may have resulted from multiple symptoms.

Featured image is from Health Impact News

The original source of this article is [Health Impact News](#)

Copyright © [Brian Shilhavy](#), [Health Impact News](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Brian Shilhavy](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants

permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca